|
1
|
Jarcho S: Diffusely infiltrative
carcinoma. Arch Pathol. 22:674–696. 1936.
|
|
2
|
Hayashi H, Haruyama H, Emura Y, Kiazuka I
and Ozeki T: Disseminated carcinomatosis of the bone marrow. Jpn J
Cancer Clin. 25:329–343. 1979.(In Japanese).
|
|
3
|
Demir L, Akyol M, Bener S, Payzin KB,
Erten C, Somali I, Can A, Dirican A, Bayoglu V, Kucukzeybek Y, et
al: Prognostic evaluation of breast cancer patients with evident
bone marrow metastasis. Breast J. 20:279–287. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kopp HG, Krauss K, Fehm T, Staebler A,
Zahm J, Vogel W, Kanz L and Mayer F: Symptomatic bone marrow
involvement in breast cancer-clinical presentation, treatment, and
prognosis: A single institution review of 22 cases. Anticancer Res.
31:4025–4030. 2011.PubMed/NCBI
|
|
5
|
Yokoyama K: A clinical study of bone
marrow involvement in non-hematological malignancies. Tokyo
Jikeikai Med J. 98:1006–1019. 1983.(In Japanese).
|
|
6
|
Papac RJ: Bone marrow metastases. A
review. Cancer. 74:2403–2413. 1994.(In Japanese).
|
|
7
|
Moriwaki S, Mandai K, Okabe K, Yamauchi M,
Yamamoto A and Kamei T: Pathological analysis for the bone marrow
metastasis by aspiration and core needle biopsy. Jpn J Cancer Clin.
49:203–209. 2003.(In Japanese).
|
|
8
|
Diel IJ, Kaufmann M, Costa SD, Holle R,
von Minckwitz G, Solomayer EF, Kaul S and Bastert G:
Micrometastatic breast cancer cells in bone marrow at primary
surgery: Prognostic value in comparison with nodal status. J Natl
Cancer Inst. 88:1652–1658. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mansi JL, Gogas H, Bliss JM, Gazet JC,
Berger U and Coombes RC: Outcome of primary-breast-cancer patients
with micrometastases: A long-term follow-up study. Lancet.
354:197–202. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Braun S, Pantel K, Müller P, Janni W, Hepp
F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, et
al: Cytokeratin-positive cells in the bone marrow and survival of
patients with stage I II, or III breast cancer. N Engl J Med.
342:525–533. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bidard FC, Vincent-Salomon A, Gomme S, Nos
C, de Rycke Y, Thiery JP, Sigal-Zafrani B, Mignot L, Sastre-Garau X
and Pierga JY; Institut Curie Breast Cancer Study Group, :
Disseminated tumor cells of breast cancer patients: A strong
prognostic factor for distant and local relapse. Clin Cancer Res.
14:3306–3311. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Langer I, Guller U, Worni M, Berclaz G,
Singer G, Schaer G, Fehr MK, Hess T, Viehl C, Bronz L, et al: Bone
marrow micrometastases do not impact disease-free and overall
survival in early stage sentinel lymph node-negative breast cancer
patients. Ann Surg Oncol. 21:401–407. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hartkopf AD, Taran FA, Wallwiener M, Hahn
M, Becker S, Solomayer EF, Brucker SY, Fehm TN and Wallwiener D:
Prognostic relevance of disseminated tumour cells from the bone
marrow of early stage breast cancer patients-results from a large
single-centre analysis. Eur J Cancer. 50:2550–2559. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kamby C, Guldhammer B, Vejborg I, Rossing
N, Dirksen H, Daugaard S and Mouridsen HT: The presence of tumor
cells in bone marrow at the time of first recurrence of breast
cancer. Cancer. 60:1306–1312. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mukaiyama T, Ogawa M, Horikoshi N, Inoue
K, Inagaki J, Egaki K, et al: Analysis of metstatic behaviors and
causes of death in 100 autopsied patients with breast cancer. Jpn J
Breast Cancer. 4:121–126. 1989.(In Japanese).
|
|
16
|
Koida T, Kimura M, Ogawa A and Sugihara S:
A study of bone marrow on autopsied cases of breast
cancer-correlated to the hormone receptor. Jpn J Breast cancer.
6:567–570. 1991.(In Japanese).
|
|
17
|
Moriwaki S, Mandai K, Ohsumi S and Doihara
H: Metastasis to bone marrow in autopsy cases of breast
cancer-focal reactions to metastasis. Jpn J Cancer Clin.
47:389–400. 2001.(In Japanese).
|
|
18
|
Evangelista L, Panunzio A, Polverosi R,
Ferretti A, Chondrogiannis S, Pomerri F, Rubello D and Muzzio PC:
Early bone marrow metastasis detection: The additional value of
FDG-PET/CT vs. CT imaging. Biomed Pharmacother. 66:448–453. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lin CY, Chen YW, Chang CC, Yang WC, Huang
CJ and Hou MF: Bone metastasis versus bone marrow metastasis?
Integration of diagnosis by (18)F-fluorodeoxyglucose positron
emission/computed tomography in advanced malignancy with super bone
scan: Two case reports and literature review. Kaohsiung J Med Sci.
29:229–233. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Delsol G, Guiu-Godfrin B, Guiu M, Pris J,
Corberand J and Fabre J: Leukoerythroblastosis and cancer
frequency, prognosis, and physiopathologic significance. Cancer.
44:1009–1013. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yachida S, Jones S, Bozic I, Antal T,
Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, et al:
Distant metastasis occurs late during the genetic evolution of
pancreatic cancer. Nature. 467:1114–1117. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Meric-Bernstam F, Frampton GM,
Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA,
Ross JS, Miller VA, Su X, et al: Concordance of genomic alterations
between primary and recurrent breast cancer. Mol Cancer Ther.
13:1382–1389. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Swanton C: Intratumor heterogeneity:
Evolution through space and time. Cancer Res. 72:4875–4882. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hilton JF, Amir E, Hopkins S, Nabavi M,
DiPrimio G, Sheikh A, Done SJ, Gianfelice D, Kanji F, Dent S, et
al: Acquisition of metastatic tissue from patients with bone
metastases from breast cancer. Breast Cancer Res Treat.
129:761–765. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bogina G, Bortesi L, Marconi M, Venturini
M, Lunardi G, Coati F, Massocco A, Manfrin E, Pegoraro C and
Zamboni G: Comparison of hormonal receptor and HER-2 status between
breast primary tumours and relapsing tumours: Clinical implications
of progesterone receptor loss. Virchows Arch. 459:1–10. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lindström LS, Karlsson E, Wilking UM,
Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L and Bergh
J: Clinically used breast cancer markers such as estrogen receptor,
progesterone receptor, and human epidermal growth factor receptor 2
are unstable throughout tumor progression. J Clin Oncol.
30:2601–2608. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Castaneda CA, Andrés E, Barcena C, Gómez
HL, Cortés-Funés H and Ciruelos E: Behaviour of breast cancer
molecular subtypes through tumour progression. Clin Transl Oncol.
14:481–485. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Simmons C, Miller N, Geddie W, Gianfelice
D, Oldfield M, Dranitsaris G and Clemons MJ: Does confirmatory
tumor biopsy alter the management of breast cancer patients with
distant metastases? Ann Oncol. 20:1499–1504. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Goldhirsch A, Winer EP, Coates AS, Gelber
RD, Piccart-Gebhart M, Thürlimann B and Senn HJ; Panel members, :
Personalizing the treatment of women with early breast cancer:
Highlights of the st gallen international expert consensus on the
primary therapy of early breast cancer 2013. Ann Oncol.
24:2206–2223. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Prat A, Cheang MC, Martín M, Parker JS,
Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen
TO and Perou CM: Prognostic significance of progesterone
receptor-positive tumor cells within immunohistochemically defined
luminal A breast cancer. J Clin Oncol. 31:203–209. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lower EE, Glass EL, Bradley DA, Blau R and
Heffelfinger S: Impact of metastatic estrogen receptor and
progesterone receptor status on survival. Breast Cancer Res Treat.
90:65–70. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Guarneri V, Giovannelli S, Ficarra G,
Bettelli S, Maiorana A, Piacentini F, Barbieri E, Dieci MV, D'Amico
R, Jovic G and Conte P: Comparison of HER-2 and hormone receptor
expression in primary breast cancers and asynchronous paired
metastases: Impact on patient management. Oncologist. 13:838–844.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Broom RJ, Tang PA, Simmons C, Bordeleau L,
Mulligan AM, O'Malley FP, Miller N, Andrulis IL, Brenner DM and
Clemons MJ: Changes in estrogen receptor, progesterone receptor and
Her-2/neu status with time: Discordance rates between primary and
metastatic breast cancer. Anticancer Res. 29:1557–1562.
2009.PubMed/NCBI
|
|
34
|
Idirisinghe PK, Thike AA, Cheok PY, Tse
GM, Lui PC, Fook-Chong S, Wong NS and Tan PH: Hormone receptor and
c-ERBB2 status in distant metastatic and locally recurrent breast
cancer. Pathologic correlations and clinical significance. Am J
Clin Pathol. 133:416–429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sari E, Guler G, Hayran M, Gullu I,
Altundag K and Ozisik Y: Comparative study of the
immunohistochemical detection of hormone receptor status and HER-2
expression in primary and paired recurrent/metastatic lesions of
patients with breast cancer. Med Oncol. 28:57–63. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yumimoto K, Akiyoshi S, Ueo H, Sagara Y,
Onoyama I, Ueo H, Ohno S, Mori M, Mimori K and Nakayama KI: F-box
protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous
manner. J Clin Invest. 125:621–635. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Takeishi S and Nakayama KI: Role of Fbxw7
in the maintenance of normal stem cells and cancer-initiating
cells. Br J Cancer. 111:1054–1059. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rahim F, Hajizamani S, Mortaz E,
Ahmadzadeh A, Shahjahani M, Shahrabi S and Saki N: Molecular
regulation of bone marrow metastasis in prostate and breast cancer.
Bone Marrow Res. 2014:4059202014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Greene FL: Breast tumoursTNM
classification of malignant tumours. 7th. Sobin LH, Gospodarowicz
MK and Wittekind C: Wiley-Blackwell; Oxford: pp. 181–193. 2009
|
